Mucosal Versus Fecal Microbiota in FMT

Status Completed

Clinical Trial Summary

Clostridium difficile infection is the most common cause of antibiotic-associated diarrhea. Treatment of this infection usually occurs using other antibiotics, but many individuals have persistent diarrhea and multiple relapses. Fecal Transplant (FMT), or Intestinal Microbiota Transplantation, (IMT) has been shown to be efficacious when administered after treatment for C. difficile. This study will involve taking biopsies from patients during their FMT/IMT via colonoscopy, and determine if there are differences in the mucosal flora as compared to the stool flora. The investigators hope to discover the critical parts of a healthy microbiota.

Clinical Trial Description

A total of 20 subjects with at least one relapse of Clostridium difficile infection undergoing Intestinal Microbiota Transplantation via colonoscopy will be recruited in this study. The patients will produce a stool specimen at the time of colonoscopy and a biopsy will be obtained during the colonoscopy. At 2 weeks and 10 weeks, stool specimens and anoscopy will be collected to be tested for C. difficile polymerase chain reaction (PCR) and the fecal microbiota. Subjects will be referred from all locations of Emory Healthcare. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clostridium Difficile

Clinical Trial Details

NCT number	NCT02133651
Study type	Observational
Source	Emory University
Contact
Status	Completed
Phase	N/A
Start date	April 2014
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02896244` - AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
Recruiting	`NCT06071312` - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach	Phase 1/Phase 2
Recruiting	`NCT01973465` - Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis	N/A
Terminated	`NCT01048567` - Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly	Phase 2
Completed	`NCT01066221` - Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile	N/A
Not yet recruiting	`NCT03586206` - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Completed	`NCT02563106` - A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI	Phase 2
Completed	`NCT02207140` - Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly	Phase 0
Completed	`NCT02857582` - Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile	Phase 2
Not yet recruiting	`NCT01942447` - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis	N/A
Active, not recruiting	`NCT01703494` - Fecal Transplant for Relapsing C. Difficile Infection	Phase 2
Completed	`NCT01813500` - Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients	N/A
Completed	`NCT01087892` - Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection	N/A
Suspended	`NCT00591357` - Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy	Phase 4
Recruiting	`NCT00377078` - Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.	N/A
Completed	`NCT02254967` - A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population	Phase 4
Terminated	`NCT01775397` - A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System	Phase 4
Terminated	`NCT03617172` - PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol	Phase 2
Recruiting	`NCT05622721` - REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
Completed	`NCT02437487` - SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)	Phase 2